Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors

Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed ... Read More